<DOC>
	<DOCNO>NCT01729351</DOCNO>
	<brief_summary>To evaluate comparative effectiveness extrafine hydrofluoroalkane beclometasone ( EF HFA-BDP ) inhale corticosteroid ( ICS ) therapy commonly use UK , specifically fluticasone ( FP ) non-extrafine ( NEF ) BDP ( CFC-BDP NEF HFA-BDP ) UK primary care asthma population current smoker .</brief_summary>
	<brief_title>Qvar Therapy Smoking Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Aged 1670 year Current smoker explicitly cod patient record capture patient questionnaire Evidence asthma diagnosis current therapy : ≥2 prescription asthma different point time baseline year ± diagnostic code asthma Ongoing asthma therapy : ≥2 prescription ICS outcome period ( i.e . ≥1 prescription addition IPD prescription ) ≥2 year continuous data ( i.e . ≥1 year baseline plus ≥1 year outcome data ) Patients exclude analysis : Any chronic respiratory disease asthma Are prescribe : Maintenance oral steroid therapy baseline year Combination ICS/longacting beta agonist ( LABA ) therapy baseline year IPD Multiple ICS prescription IPD immediately .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Primary Care</keyword>
	<keyword>Particle size</keyword>
	<keyword>beclomethasone dipropionate</keyword>
	<keyword>Asthma Management</keyword>
	<keyword>Maintenance Therapy</keyword>
	<keyword>Metered-Dose Inhaler</keyword>
	<keyword>Smoking</keyword>
</DOC>